These results came shortly after Pfizer announced that their vaccine had similar efficacy. This gives hope that the vaccines will help stop the pandemic.
–
“Moderna” have announced that this is a “big day” and that in the coming weeks it is planned to submit the vaccine for approval.
–
However, it should be noted that these are preliminary data and studies are ongoing.
–
The Modern study involved 30,000 people in the US, half of whom received two doses of the vaccine four weeks apart.
–
The current data analyze the first 95 cases of Covid-19 symptoms in participants.
–
Only in five cases were those who received the vaccine infected, and in 90 cases those who received a false injection. The company claims that the vaccine is 95.5% effective.
–
The data also show that 11 patients had severe disease, but all cases were those who did not receive the vaccine.
–
True, it is still unknown how long the immunity will last. Volunteers will have to follow the situation for a long time in order to answer this question. There are also no data on how well the vaccine works in the elderly at risk of Covid-19.
–
However, a spokesman for Moderna told the BBC that current data did not suggest that the vaccine would lose its ability over time.
–
It is also not known whether the vaccine only protects against serious illness or whether it stops the virus from spreading.
–
No serious safety risks were reported in the study and it should be noted that no drug is completely safe. Some patients have reported short-term fatigue, headaches and muscle aches after the injection.
— .
/data/photo/2020/11/16/5fb2394ed9f29.jpg?resize=150%2C150&ssl=1 "All Women Are At Risk Of Down Birth, This Is The Diagnosis And Handling Page all")